California Public Employees Retirement System lowered its stake in shares of ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) by 8.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,275 shares of the company’s stock after selling 5,052 shares during the quarter. California Public Employees Retirement System owned approximately 0.16% of ShockWave Medical worth $10,949,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Parallel Advisors LLC increased its position in shares of ShockWave Medical by 6.6% in the 2nd quarter. Parallel Advisors LLC now owns 938 shares of the company’s stock worth $179,000 after purchasing an additional 58 shares during the last quarter. Fifth Third Bancorp increased its holdings in ShockWave Medical by 3.1% in the second quarter. Fifth Third Bancorp now owns 2,084 shares of the company’s stock valued at $398,000 after buying an additional 62 shares during the last quarter. Lincoln National Corp increased its holdings in ShockWave Medical by 6.6% in the second quarter. Lincoln National Corp now owns 1,089 shares of the company’s stock valued at $208,000 after buying an additional 67 shares during the last quarter. Arizona State Retirement System raised its stake in ShockWave Medical by 0.9% during the first quarter. Arizona State Retirement System now owns 8,589 shares of the company’s stock valued at $1,781,000 after buying an additional 74 shares in the last quarter. Finally, Private Capital Group LLC lifted its holdings in ShockWave Medical by 42.0% during the 2nd quarter. Private Capital Group LLC now owns 257 shares of the company’s stock worth $49,000 after buying an additional 76 shares during the last quarter. Institutional investors own 95.40% of the company’s stock.
Insider Activity at ShockWave Medical
In other ShockWave Medical news, Director Frank T. Watkins sold 3,000 shares of the business’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $244.44, for a total transaction of $733,320.00. Following the completion of the transaction, the director now owns 3,796 shares in the company, valued at approximately $927,894.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other ShockWave Medical news, CEO Douglas Evan Godshall sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $240.81, for a total transaction of $7,224,300.00. Following the transaction, the chief executive officer now owns 82,926 shares of the company’s stock, valued at approximately $19,969,410.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Frank T. Watkins sold 3,000 shares of the business’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $244.44, for a total transaction of $733,320.00. Following the sale, the director now owns 3,796 shares in the company, valued at $927,894.24. The disclosure for this sale can be found here. Insiders have sold a total of 57,350 shares of company stock worth $14,927,408 in the last three months. 3.90% of the stock is owned by company insiders.
ShockWave Medical Stock Performance
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on SWAV shares. Bank of America boosted their price target on ShockWave Medical from $260.00 to $310.00 in a report on Monday, November 7th. Piper Sandler lifted their price target on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an “overweight” rating in a report on Monday, August 29th. Wells Fargo & Company increased their price objective on shares of ShockWave Medical from $255.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 8th. Canaccord Genuity Group lifted their target price on ShockWave Medical from $232.00 to $256.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Finally, Oppenheimer cut ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 price target on the stock. in a research report on Tuesday, September 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, ShockWave Medical currently has an average rating of “Moderate Buy” and a consensus price target of $263.00.
ShockWave Medical Company Profile
ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.
- Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.